Giuseppe Biondi Zoccai Giuseppe Biondi Zoccai Interventional Cardiology, University of Interventional Cardiology, University of Turin, Italy Turin, Italy [email protected][email protected]PCI in diabetics and PCI in diabetics and diffuse disease: role of diffuse disease: role of IIb/IIIa inhibitors IIb/IIIa inhibitors
50
Embed
Giuseppe Biondi Zoccai Interventional Cardiology, University of Turin, Italy [email protected] PCI in diabetics and diffuse disease: role of IIb/IIIa.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Giuseppe Biondi ZoccaiGiuseppe Biondi Zoccai
Interventional Cardiology, University of Turin, ItalyInterventional Cardiology, University of Turin, Italy
• What is the evidence base on of IIb/IIIa inhibitors
in diabetics undergoing PCI?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa What is the role of IIb/IIIa inhibitors in PCI of diabetics?inhibitors in PCI of diabetics?
Meta-analysis of RCTMeta-analysis of RCT
Reduction in mortality @ 1 monthReduction in mortality @ 1 month
Karvouni, JACC 2003
Survival benefit in DM & ACSSurvival benefit in DM & ACS
Roffi, Circ 2001
ADVANCE trialADVANCE trial
Valgimigli, JACC 2004
Any doubt?Any doubt?
ISAR-SWEET trial
DES deployed in
only 10% of pts
Mehilli, Circ 2004
BARE31.9% Abc40.2% PlaP=0.04
DES7.3% Abc4.9% PlaP=NS
ISAR-SWEET ISAR-SWEET
Mehilli, Circ 2004
Paradoxical results of TAXUS IVParadoxical results of TAXUS IV
Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent : A TAXUS IV Substudy
Ideal anti-thrombotic strategy in patients undergoing percutaneous coronary interventions (PCI) is still a matter of controversy. A number of studies have shown that while a combination of glycoprotein IIb/IIIa inhibitors with weight adjusted heparin improves anti-ischemic efficacy (particularly decreasing peak CK-MB iso-enzyme elevation after PCI) it still increases the vascular complications after the procedure. Use of bivalirudin may prove equally efficacious (also in reducing peak CK-MB elevation) without increasing the risk of bleeding. However, it is limited by issues of non-reversibility of bivalirudin effect. However, these data have not been rigorously tested in the era of drug eluting stents. Teirstein and co-workers performed a prespecified subgroup analysis of the TAXUS IV study population to examine the effect of procedural glycoprotein IIb/IIIa inhibition during paclitaxel-eluting stent implantation on periprocedural creatine kinase-MB (CK-MB) levels. Glycoprotein (GP) IIb/IIIa inhibitors were administered to 57.7% of patients who had been randomized to receive the TAXUS stent and to 56.7% of those who had been randomized to receive the control stent. Among patients who received the TAXUS stent, the rate of CK-MB increases of >3 times the normal level was 2.6-fold higher in those who received a GP IIb/IIIa inhibitor than in those who did not (11.4% vs 4.4%, p = 0.0015). Composite rates of major adverse cardiac events and target vessel failure were also higher at 1 month in the GP IIb/IIIa group. By multivariate analysis, use of GP IIb/IIIa inhibitors during stenting with the TAXUS stent was an independent predictor of CK-MB increases >3 times the normal level. However, the issue is far from closed, further studies are warranted to confirm the present findings and to look for the mechanisms of the same.
Teirstein, Am J Cardiol 2005
ISAR-REACT 2 trialISAR-REACT 2 trial
DES deployed
in 50% of pts
Kastrati, JAMA 2006
Prevention of intraprocedural Prevention of intraprocedural drug-eluting stent thrombosisdrug-eluting stent thrombosis
The occurrence of intra-procedural stent thrombosis (IPST) was analyzed across 1,320 patients undergoing drug-eluting stenting in 4 Italian centers.IPST occurred in 6 (0.5%), with in-hospital major adverse events in 4 (67%). By pooling results of the present study with those of a previous study, for a total of 2,235 patients, elective glycoprotein IIb/IIIa inhibitors appeared to significantly prevent the occurrence of IPST, because no IPST occurred among patients treated with glycoprotein IIb/IIIa inhibitors (0 of 725), whereas all IPST occurred in the absence of adequate upfront IIb/IIIa inhibition treatment (11 of 1,510 [0.7%], odds ratio=0.24 [95% confidence interval 0.06 to 0.97], p=0.036).
Biondi-Zoccai, AJC 2005
Biondi-Zoccai, AJC 2005
0,54
0
0,45
0
0,49
00
0,2
0,4
0,6
0,8
1
Chieffo et al(N=915)
RECIPE(N=1320)
Pooled estimate(N=2235)
no IIb/IIIa
IIb/IIIa
%%Odds ratio=0.24 p=0.034Odds ratio=0.24 p=0.034
Prevention of intraprocedural Prevention of intraprocedural drug-eluting stent thrombosisdrug-eluting stent thrombosis
• What is the pathophysiology underlying the
increased peri-PCI risk of diabetics?
• What is the evidence base on of IIb/IIIa inhibitors
in diabetics undergoing PCI?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa What is the role of IIb/IIIa inhibitors in PCI of diabetics?inhibitors in PCI of diabetics?
• What is the pathophysiology underlying the
increased peri-PCI risk in diffuse disease?
• What is the evidence base on of IIb/IIIa inhibitors
in patients with diffuse disease?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa inhibitors What is the role of IIb/IIIa inhibitors in PCI of diffuse disease?in PCI of diffuse disease?
• What is the pathophysiology underlying the
increased peri-PCI risk in diffuse disease?
• What is the evidence base on of IIb/IIIa inhibitors
in patients with diffuse disease?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa inhibitors What is the role of IIb/IIIa inhibitors in PCI of diffuse disease?in PCI of diffuse disease?
Impact of plaque burdenImpact of plaque burden
Porto, Circ 2006
Predictors of intraprocedural stent Predictors of intraprocedural stent thrombosis in the RECIPE Studythrombosis in the RECIPE Study
Biondi-Zoccai, AJC 2005
IPST No IPST
Variable n=6 n=1314 P
Multiple stenting in the same lesion 3 (50%) 155 (12%) 0.027
Hazards of multivessel Hazards of multivessel DES implantation DES implantation
Orlic, JACC 2004
But:
CK-MB 3xULN in 26
(16.8%) patients;
specifically 17
[12.8%] with 2VD
SES implantation
and in 9 [32.1%]
patients with 3VD
SES implantation
Overlapping DESOverlapping DES
TAXUS V- the impact on side branches TAXUS V- the impact on side branches in the overlap region (per side branch)in the overlap region (per side branch)
Control TAXUS
51/20351/203 68/20768/207 12/4812/48 26/5526/55
Any TIMI FlowAny TIMI FlowReductionReduction
Non-overlapNon-overlap
regionregion
OverlapOverlap
regionregion
25.1 25.0
32.9
47.3
p=0.10 p=0.025
Possible Causes for TIMI Flow Reduction?•Plaque burden & “snowplow” effect•Jailing of the side branch
Impact of increased strut width
Macro Strut Width •TAXUS 120 µm•Express2 90 µm
•33% increase in total strut width
Hazards of overlapping DES Hazards of overlapping DES implantation in diffuse diseaseimplantation in diffuse disease
Tsagalou, JACC 2005
• What is the pathophysiology underlying the
increased peri-PCI risk in diffuse disease?
• What is the evidence base on of IIb/IIIa inhibitors
in patients with diffuse disease?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa inhibitors What is the role of IIb/IIIa inhibitors in PCI of diffuse disease?in PCI of diffuse disease?
Mortality at 30 days
Karvouni, JACC 2003
Role of IIb/IIIa inhibitors in ACS
Consisting of peri-procedural IIb/IIIa inhibitors (p=0.041)
and/or thienopyridines (p=0.091)
Biondi-Zoccai, Am Heart J 2005
Prevention of acute drug-Prevention of acute drug-eluting stent thrombosiseluting stent thrombosis
Biondi-Zoccai, AJC 2005
0,54
0
0,45
0
0,49
00
0,2
0,4
0,6
0,8
1
Chieffo et al(N=915)
RECIPE(N=1320)
Pooled estimate
no IIb/IIIa
IIb/IIIa
%%Odds ratio=0.24 P=0.034Odds ratio=0.24 P=0.034
• What is the pathophysiology underlying the
increased peri-PCI risk in diffuse disease?
• What is the evidence base on of IIb/IIIa inhibitors
in patients with diffuse disease?
• Which additional treatments should be
recommended in diabetics or diffuse CAD?
What is the role of IIb/IIIa inhibitors What is the role of IIb/IIIa inhibitors in PCI of diffuse disease?in PCI of diffuse disease?
Herrmann, EHJ 2005
Additional treatmentsAdditional treatments
++
+/-+/-
++++++
++++++++
+/-+/-
+/-+/-
Superiority of a high (Superiority of a high (>>600 mg) 600 mg) clopidogrel loading doseclopidogrel loading dose
Outcome:Outcome: One-month death or myocardial infarction One-month death or myocardial infarction
Study High loading Low loading Peto OR Peto ORor sub-category n/N n/N 95% CI 95% CI
So what is the state of the art treatment?So what is the state of the art treatment?
FREEDOMFREEDOM
MV-stentingMV-stentingWith DES and ReoProWith DES and ReoPro
Eligibility : DM patients with MV-CAD eligible for stent or surgeryEligibility : DM patients with MV-CAD eligible for stent or surgeryExclude : Patients with acute STEMI, cardiogenic shockExclude : Patients with acute STEMI, cardiogenic shock
CABGCABGWith or without CPBWith or without CPB
All concomitant Meds shown to be beneficial are encouraged, including : All concomitant Meds shown to be beneficial are encouraged, including : Plavix, ACE inhibitors,Plavix, ACE inhibitors, -blockers, statins etc-blockers, statins etc
PRIMARY: 5-year mortalityPRIMARY: 5-year mortalitySECONDARY: 12-month MACCE, 5-year Quality of LifeSECONDARY: 12-month MACCE, 5-year Quality of Life
Randomized 1:1
Integrilin plus STenting to Integrilin plus STenting to
Coronary angiogram showing significant nativecoronary lesion treatable by means of >33 mm of DES
Administration of 600 mg clopidogrel loading and heparin bolus in the catheterization laboratory
Take home messages Take home messages for successful PCI for successful PCI
• Gp IIb/IIIa inhibitors provided significant benefits in diabetics treated with PTCA or BMS
• The introduction of high-dose clopidogrel loading has significantly improved peri-procedural outcomes, and likely limited the use of Gp IIb/IIIa inhibitors to selected cases (ie high-risk and/or ACS)
• Their impact in diabetics undergoing PCI in the DES era has not yet been thoroughly established, but lack of evidence for an effect cannot be considered evidence for lack of an effect
• Given the absence of specific data on diffuse disease, precise inference in this setting will have to wait for ongoing and future trials
Take home messagesTake home messages
For further slides on these topics please feel free to visit the metcardio.org website: